GCLLSG patients treated with alemtuzumab : results from the CLL 2 H trial of the mutations in fludarabine-refractory CLL
暂无分享,去创建一个
M. Cazzola | K. Döhner | H. Döhner | P. Paschka | M. Hallek | S. Stilgenbauer | T. Zenz | D. Winkler | D. Mertens | A. Bühler | J. Edelmann | R. Busch | M. Rossi | Sabrina Kless | S. Mack | A. Schnaiter
[1] M. Cazzola,et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.
[2] N. Schmitz,et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. , 2013, Blood.
[3] G. Juliusson,et al. NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia , 2013, Leukemia.
[4] D. Catovsky,et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.
[5] J. Gribben,et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. , 2012, Blood.
[6] Y. Pekarsky,et al. NOTCH1 mutations in CLL associated with trisomy 12. , 2012, Blood.
[7] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[8] Luca Laurenti,et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. , 2012, Blood.
[9] L. Pasqualucci,et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.
[10] A. Sivachenko,et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.
[11] L. Pasqualucci,et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.
[12] H. Döhner,et al. From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.
[13] R. Schlenk,et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Axel Benner,et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.
[15] Andrew P. Weng,et al. Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.
[16] Axel Benner,et al. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.
[17] H. Kantarjian,et al. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.
[18] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[19] E. Thiel,et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.